A Review on the New and Old Anticoagulants.
A Review on the New and Old Anticoagulants.
复制标题
DOI：
10.1097/nor.0000000000000517
复制
发表时间：
2019-01
期刊：
影响因子：
--
通讯作者：
Kayla Myers;A. Lyden
中科院分区：
文献类型：
--
作者：
Kayla Myers;A. Lyden
抗凝剂是预防和治疗动脉和静脉血栓栓塞的主要策略。抗凝剂通过干扰凝血级联中的各个点来破坏凝血。这类药物不会溶解已经存在的凝块;相反，它可以防止血栓形成，防止或减缓现有凝块的扩展。几十年来，需要口服抗凝治疗的患者的标准治疗方法是华法林。然而，由于华法林的一些缺点，包括需要持续的常规监测、抗凝作用的长期起效和抵消、主要的食物和药物相互作用以及出血的高发生率，开发了称为直接口服抗凝剂或DOAC的新药物。本文将提供一个审查的临床重要信息，最常用的抗凝剂和逆转剂。
Anticoagulants serve as the primary strategy for the prevention and treatment of both arterial and venous thromboembolism. Anticoagulants disrupt coagulation by interfering at various points in the coagulation cascade. This class of medications does not lyse clots that already exist; rather, it prevents thrombus formation and prevents or slows the extension of an existing clot. For decades, the standard therapy for patients requiring oral anticoagulation was warfarin. However, due to some of the shortcomings of warfarin, including the need for continuous routine monitoring, longtime onset and offset of anticoagulation effect, major food and drug interactions, and high incidence of bleeding, newer agents, termed direct oral anticoagulants, or DOACs were developed. This article will provide a review of clinically important information regarding the most commonly used anticoagulants and their reversal agents.